文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

延长输注β-内酰胺类抗生素治疗血液病患者发热性中性粒细胞减少症:BEATLE随机对照优效性试验方案

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).
PubMed 文献 · Trials · 2020-05-18

BEATLE试验为多中心、开放标签、优效性随机对照IV期研究,拟在化疗或造血干细胞移植后出现发热性中性粒细胞减少(FN)的血液恶性肿瘤患者中,比较头孢吡肟、哌拉西林-他唑巴坦或美罗培南延长输注(EI)与间歇输注(II)的临床疗效。主要终点为治疗前5天内退热且不调整抗生素治疗,在意向治疗人群中分析。该研究旨在验证EI在FN患者中临床疗效优于II的假设。

要点

  • FN患者中比较β-内酰胺类抗生素EI与II的临床疗效。
  • 主要终点为5天内退热且不调整抗生素。
  • EI输注时间为给药间隔的一半,II为30分钟。

核心结论

  • 该方案拟验证在血液病FN患者中β-内酰胺类抗生素延长输注较间歇输注临床疗效更优的假设。

研究设计与样本

  • 随机、多中心、开放标签、优效性IV期临床试验。
  • 纳入化疗或造血干细胞移植后出现FN并接受头孢吡肟、哌拉西林-他唑巴坦或美罗培南经验性治疗的血液恶性肿瘤患者。
  • 按1:1随机分为EI组(输注时间为给药间隔的一半)和II组(30分钟)。
  • 主要终点在意向治疗人群中分析。

关键数值与推荐

  • 主要终点为治疗前5天内退热且不调整抗生素治疗。
  • 次要终点包括PK/PD靶目标达成、菌血症清除、C反应蛋白下降、30天总体病死率、不良事件及群体PK模型建立。
  • 试验注册号:EudraCT 2018-001476-37;ClinicalTrials.gov NCT04233996。

临床怎么用

  • 若试验验证EI优于II,可能改变血液病FN高危患者的日常抗生素管理以改善结局。

局限性

  • 目前仅有3项相关临床研究且结果矛盾,并存在方法学缺陷限制其发现解读。
  • FN患者中关于β-内酰胺类抗生素给药策略的数据匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. METHODS: A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. DISCUSSION: Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. TRIAL REGISTRATION: European Clinical Trials Database: EudraCT 2018-001476-37. ClinicalTrials.gov, ID: NCT04233996.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Laporte-Amargos J, Gudiol C, Arnan M, et al. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials. 2020. PMID: 32423462. doi:10.1186/s13063-020-04323-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。